Celldex's barzolvolimab meets Phase 3 goals but safety concerns emerge
read at Endpoints ↗Positive readoutNeutral
Celldex announced that its experimental chronic hives treatment, barzolvolimab, achieved the primary endpoint in two Phase 3 trials.
The trials demonstrated the drug's efficacy in reducing hive symptoms, marking a significant milestone for the company.
At the same time, the readout disclosed two life‑threatening allergic reactions that occurred after administration, prompting serious safety concerns.
Celldex will need to address these safety issues before proceeding with further regulatory steps or broader market rollout.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Celldex's hives drug faces safety questions despite Phase 3 successes”
read at Endpoints ↗87 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that